Gynecologic Oncologist Joins Cancer Center at University Hospital
He began seeing
Richards specializes is treating pre-cancerous and cancerous conditions in the reproductive tract. He has more than 10 years of experience as an attending physician, providing care for patients with gynecologic cancers, which include diseases that involve the cervix, ovaries, uterus, and vulva. He also performs minimally invasive surgical procedures, including robotic surgery.
Historically, open and laparoscopic (minimally invasive) abdominal surgery has been considered the standard of care for gynecologic cancers. Although not applicable to every patient or disease process, Richards says minimally invasive surgical procedures have become appropriate in certain cases.
Robotic surgery is a method of operating inside the abdomen using robotic "arms and specialized instruments inserted through small incisions (about half an inch each) into the body. The surgeon controls the operative arms from a computer console.
"Patients who undergo robotic surgery typically experience less post-operative pain and shorter recovery times when compared to traditional open surgical methods, Richards explains. "A cancer diagnosis is stressful enough without the added frustration of a long post-surgical recovery period.
As director of womens cancer, Richards will play a key role in the joint cancer program.
The joint cancer program is a collaborative initiative involving the UC College of Medicine, Cincinnati Childrens
He says his long-term vision is to create an all-inclusive womens cancer program at Barrett Cancer Center that offers cutting edge medical therapies, clinical trials, screening programs and patient support services such as counseling, nutritional coaching, relaxation therapy and other aesthetic services.
"My goal is to transform an area that has historically been one of the most stressful places for patientsa cancer treatment centerinto a positive place where their fears are calmed and their ailments are addressed and potentially eliminated, he explains.
In addition to providing comprehensive gynecologic surgery and chemotherapy services, Richards will lead a robust clinical trials program to investigate new screening methods aimed at early disease detection and treatment strategies that may improve patient survival.
"In the past, most clinical cancer research has focused on prolonging patients lives after their diagnosisa method that yields small gains, says Richards. "Our research is beginning to focus on evaluating new treatment strategies, vaccines, genetic risk factors and other variables to identify, evaluate and treat women at risk for gynecologic cancers.
Richards joins UC from Gynecologic Oncology Associates, a successful combined private- and university-based practice in
Richards is board certified by the American Board of Obstetrics and Gynecology in both gynecologic oncology and general obstetrics/gynecology.
A
To schedule an appointment with Richards at the
For more information on gynecologic cancer clinical trials, call (513) 584-7698.
Related Stories
Make Hoxworth Blood Center’s special holiday events part of your family celebrations this December
December 12, 2025
This December, Hoxworth Blood Center, University of Cincinnati, is inviting families across Greater Cincinnati to add something truly meaningful to their holiday traditions: giving the gift of life. With festive community events, beloved local partners and special thank-you gifts for donors, Hoxworth is making it easier, and more heartwarming than ever, to roll up your sleeves and help save lives close to home.
Ohio nurses weigh in on proposed federal loan rule
December 12, 2025
Spectrum News journalist Javari Burnett spoke with UC Dean Alicia Ribar and UC nursing students Megan Romero and Nevaeh Haskins about proposed new federal student loan rules. Romero and Haskins, both seniors, were filmed in the College of Nursing’s Simulation Lab.
New combination treatment improves multiple myeloma outcomes
December 11, 2025
The University of Cincinnati Cancer Center's Ed Faber, DO, provided commentary to Medscape on the COBRA study that found the combination of carfilzomib combined with lenalidomide and dexamethasone (KRd) shows significantly greater efficacy than the previous standard of care.